LL‐37 Inhibits TMPRSS2 ‐Mediated S2 ' Site Cleavage and SARS‐CoV‐2 Infection but Not Omicron Variants
Cell Proliferation · 2025
DOI: 10.1111/cpr.70060 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cell Proliferation, 2025. Verfasst von Zhenfei Bi und 10 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Aging Research and Cancer Drug Target, State Key Laboratory of Biotherapy, National Clinical Research Center for Geriatrics, West China…. Hauptthemen laut MEDLINE: Serine Endopeptidases, SARS-CoV-2, Cathelicidins, Spike Glycoprotein, Coronavirus. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 79 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The National Science Foundation for Excellent Young Scholars, National Natural Science Foundation Regional Innovation and Development, China Postdoctoral Science Foundation.
Abstract (Originalsprache)
Continual evolution of SARS‐CoV‐2 spike drives the emergence of Omicron variants that show increased spreading and immune evasion. Understanding how the variants orientate themselves towards host immune defence is crucial for controlling future pandemics. Herein, we demonstrate that human cathelicidin LL‐37, a crucial component of innate immunity, predominantly binds to the S2 subunit of SARS‐CoV‐2 spike protein, occupying sites where TMPRSS2 typically binds. This binding impedes TMPRSS2‐mediated priming at site S2' and subsequent membrane fusion processes. The mutation N764K within S2 subunit of Omicron variants reduces affinity for LL‐37 significantly, thereby diminishing binding capacity and inhibitory effects on membrane fusion. Moreover, the early humoral immune response enhanced by LL‐37 is observed in mice against SARS‐CoV‐2 spike but not Omicron BA.4/5 spike. These findings reveal the mechanism underlying interactions amongst LL‐37, TMPRSS2 and SARS‐CoV‐2 and VOCs, and highlight the distinct mutation for Omicron variants to evade the fusion activity inhibition by host innate immunity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Aging Research and Cancer Drug Target, State Key Laboratory of Biotherapy, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, China.
- Department of Hepatobiliary Surgery, Xinqiao Hospital, Army Medical University, Chongqing, China.
- Institute of Biomedicine and Biotechnology, Shenzhen Institute of Advanced Technology, Chinese Academy of Science, Shenzhen, China.
ORCID-Profile: Wenyan Ren, Xiawei Wei
Förderung
- The National Science Foundation for Excellent Young Scholars
- National Natural Science Foundation Regional Innovation and Development
- China Postdoctoral Science Foundation
- Sichuan Provincial Natural Science Foundation for Young Scholars
Zitieren
APA
Bi, Z., Ren, W., Zeng, H., Zhou, Y., Liu, J., Chen, Z., Zhang, X., He, X., Lu, G., Wei, Y., & Wei, X. (2025). LL‐37 Inhibits TMPRSS2 ‐Mediated S2 ' Site Cleavage and SARS‐CoV‐2 Infection but Not Omicron Variants. Cell Proliferation. https://doi.org/10.1111/cpr.70060
Vancouver
Bi Z, Ren W, Zeng H, Zhou Y, Liu J, Chen Z, et al. LL‐37 Inhibits TMPRSS2 ‐Mediated S2 ' Site Cleavage and SARS‐CoV‐2 Infection but Not Omicron Variants. Cell Proliferation. 2025. doi:10.1111/cpr.70060
BibTeX
@article{Bi2025,
author = {Bi, Zhenfei and Ren, Wenyan and Zeng, Hao and Zhou, Yuanyuan and Liu, Jian and Chen, Zimin and Zhang, Xindan and He, Xuemei and Lu, Guangwen and Wei, Yuquan and Wei, Xiawei},
title = {LL‐37 Inhibits TMPRSS2 ‐Mediated S2 ' Site Cleavage and SARS‐CoV‐2 Infection but Not Omicron Variants},
journal = {Cell Proliferation},
year = {2025},
doi = {10.1111/cpr.70060}
}
EUVIMED